Success Metrics

Clinical Success Rate

80.0%

Based on 4 completed trials

Completion Rate

80%(4/5)

Active Trials

2(25%)

Results Posted

0%(0 trials)

Terminated

1(13%)

Phase Distribution

Ph phase_4

88%

Ph not_applicable

13%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution8 total trials

Phase 4Post-market surveillance

7(87.5%)

N/ANon-phased studies

1(12.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(2)

Completed(4)

Terminated(1)

Other(1)

Detailed Status

Completed4

Recruiting2

Terminated1

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

80.0%

Most Advanced

Phase 4

Trials by Phase

Phase 47 (87.5%)

N/A1 (12.5%)

Trials by Status

terminated113%

recruiting225%

unknown113%

completed450%

Recent Activity

2 active trials

Showing 5 of 8

completedphase_4

Clinical Trials (8)

Showing 8 of 8 trials

NCT04080661Phase 4

Therapeutic Drug Monitoring of Secukinumab in Psoriasis Patients.

Completed

NCT04080635Not Applicable

Therapeutic Drug Monitoring of Brodalumab in Psoriasis Patients (BIOLOPTIM-BRO)

Recruiting

NCT04028713Phase 4

Dose Tapering Study of Adalimumab in Psoriasis

Terminated

NCT04080648Phase 4

Therapeutic Drug Monitoring of Guselkumab in Psoriasis Patients

Completed

NCT04083612Phase 4

Therapeutic Drug Monitoring of Ixekizumab in Psoriasis Patients

Completed

NCT05685940Phase 4

Therapeutic Drug Monitoring of Risankizumab in Psoriasis Patients (BIOLOPTIM-RIS)

Recruiting

NCT05683015Phase 4

Therapeutic Drug Monitoring of Tildrakizumab in Psoriasis Patients

Unknown

NCT05683054Phase 4

A Non-inferiority Study on Dose Reduction of Adalimumab in Psoriasis Patients Who Are Overtreated

Completed

All 8 trials loaded

Drug Details

Intervention Type: PROCEDURE
Total Trials: 8